Use of Maraviroc in the prevention and Treatment of Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated Progressive Multifocal LeukoencephalopathyDeepti Anbarasan1*, Jonathan Howard1,2 and Lana Zhovtis Ryerson1,2
- Corresponding Author:
- Deepti Anbarasan
New York University School of Medicine
Department of Neurology
240 East 38th Street – 20th Floor
New York, NY, USA 10016
E-mail: [email protected]
Received date: July 25, 2014; Accepted date: September 16, 2014; Published date: September 19, 2014
Citation: Anbarasan D, Howard J, Ryerson LZ (2014) Use of Maraviroc in the prevention and Treatment of Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. J Mult Scler 1:116. doi:10.4172/2376-0389.1000116
Copyright: © 2014 Anbarasan D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
We discuss the case of a patient with Progressive Multifocal Leukoencephalopathy (PML), developed after treatment with Natalizumab for 42 months for relapsing remitting multiple sclerosis (RRMS). Imaging was consistent with wide-spread PML with features that portended a high risk of development of Immune Reconstitution Inflammatory Syndrome (IRIS). After completion of plasmapheresis, she was started on oral maraviroc, chemokine receptor 5 antagonists. Our patient did not develop radiological signs or symptoms of clinical IRIS and tolerated maraviroc without adverse side-effects. We propose that maraviroc merits further examination as an agent that may prevent IRIS in patients with natalizumab-associated PML.